SG3511

SG3511 is a non-targeting peptide-drug conjugate (PDC) primarily utilized as a negative control in preclinical oncology research. It consists of a non-binding control peptide conjugated to the potent DNA-binding pyrrolobenzodiazepine (PBD) dimer payload, tesirine (also known as SG3249), via a protease-cleavable valine-alanine linker. SG3511 is used to establish the baseline, target-independent toxicity of the PBD payload and to validate the specificity and therapeutic index of targeted PDCs, such as the integrin αvβ6-targeting conjugate SG3299. Developed through collaborations involving ADC Therapeutics, Spirogen, and the Barts Cancer Institute, SG3511 serves as a critical tool for evaluating the efficacy of peptide-mediated delivery systems in models of pancreatic ductal adenocarcinoma (PDAC) and other solid tumors.